Skip to main content
Cureus logoLink to Cureus
. 2018 Mar 9;10(3):e2297. doi: 10.7759/cureus.2297

Desmoid Tumor as an Initial Presentation of Familial Adenomatous Polyposis: A Review of the Literature

Fady G Haddad 1,✉, Sandy El Bitar 2, Iskandar Barakat 3, Liliane Deeb 4
Editors: Alexander Muacevic, John R Adler
PMCID: PMC6710485  PMID: 31482042

Abstract

Desmoid tumors (DTs) are rare soft tissue neoplasms, especially when originating from the small bowel. An association with familial adenomatous polyposis (FAP) of the colon has been well documented. Within the FAP population, there is a strong correlation between prophylactic procto-colectomy and subsequent development of DTs. Very few reports describe cases of FAP initially presenting with desmoid-related complications. Therefore, we underwent a review of the literature in order to delineate the characteristics of desmoid tumors occurring as an initial presentation of FAP.

Keywords: desmoid tumors, familial adenomatous polyposis, fibromatosis

Introduction and background

Desmoid tumors or fibromatosis are rare soft tissue neoplasms, especially when originating from the small bowel. They commonly affect the mesenchymal tissues intra-abdominally, within the abdominal wall or in the limb girdle. Their association with familial adenomatous polyposis of the colon (FAP) and Gardner’s syndrome has been well documented. It is reported that abdominal wall and intra-abdominal desmoids occur more frequently in FAP patients, and the incidence ranges from 3.5% to 32%. Within the FAP population, there is a strong correlation between prophylactic procto-colectomy and the subsequent development of desmoid tumors. However, it is rather uncommon for FAP to initially present with desmoid-related complications [1-2].

The term “desmoid” meaning tendon or band in Greek was first used by the German physiologist and comparative anatomist Johannes Müller in 1838. Desmoid tumors (DTs) form only 0.03% of all tumors. Predisposing factors to DT include female gender, prior abdominal trauma or surgery, and family history of fibromatoses. Differential diagnosis include gastrointestinal stromal tumors, lymphoma, and sarcoma. DTs can be primary or secondary. Primary or sporadic DTs are extremely rare and originate from the proliferation of fibroblasts-myofibroblasts with the formation of benign stromal neoplasms. Secondary DTs are commonly associated with hereditary polyposis syndromes with 30% of FAP patients developing intra-abdominal desmoids disease, including tumors, nodules, and sheet-like lesions. They can also occur secondary to trauma or hormonal stimulation [1-2].

Review

DTs are classified into abdominal wall, extra-abdominal, and intra-abdominal based on their location and clinico-pathological findings. Abdominal wall DTs are proliferative fibrous tumors. Extra-abdominal DTs are histologically similar but more invasive than intra-abdominal DTs. DTs that occur intra-abdominally arise from the mesentery in 85% of cases. Confirmation is based on histo-pathological examination where the findings of spindle- or stellate-shaped fibroblasts in a collagenous stroma favor the diagnosis of DT. Imaging studies such as computed tomography (CT) scan and magnetic resonance imaging (MRI) are often used to delineate the anatomical location and extension of the tumor [3-5].

Small bowel obstruction (SBO) is a common complication of desmoid tumors which is reported in 27% to 58% of patients with FAP-related desmoid tumors in previous studies. However, it is uncommon for FAP to initially present with SBO secondary to DT. In this setting, SBO can be caused either by direct mass effect due to tumor growth, or infiltration of the mesentery by tumor cells causing wrinkling of the bowel margin and sclerosis of the mesenteric vessels which leads to ischemic stricture formation. SBO recurrence is not uncommon and confirms the progressive nature of the disease, as a recent study showed that around two-thirds of patients had one recurrence and up to one-third had a second recurrence. Formation of multiple strictures is often described and attributed to the ability of DT to occur at multiple sites. Other complications of mesenteric DTs include ureteric obstruction, intestinal perforation, entero-cutaneous fistulae, and intestinal hemorrhage [3-5].

Desmoid lesions in FAP are also characterized by the involvement of the mesentery and abdominal wall in the majority of cases, and tumors are often multiple in this setting. Mesenteric DTs present with insidious symptoms that usually occur when the tumor is large enough to cause abdominal discomfort and pain. In addition, mesenteric DTs do not metastasize but they may be locally aggressive. They are similar to fibrosarcoma and fibrous lesions in their biological behavior [6-7].

Initial management includes upper and lower endoscopy to exclude any associated polyposis syndromes. If a polyposis syndrome is found, medical therapy is preferred in view of the high recurrence rate, the practical difficulty, and the risks associated with surgical approaches unless a strict surgical indication is present. First line medications consist of non-steroidal anti-inflammatory drugs (NSAIDs), tamoxifen and other chemotherapeutic agents namely vinblastine, methotrexate, doxorubicin, dacarbazine, and carboplatin. However, surgery is the preferred modality for sporadic DT as recurrence rate is low [6-7].

Prognosis depends on the location of these tumors. Intra-abdominal DTs are associated with unfavorable outcomes because of the increased rate of associated complications like bowel obstruction, bleeding, entero-cutaneous fistulae, and perforation. In cases of retroperitoneal involvement, DTs could result in major blood vessels compression and ureteral obstruction [6-7].

Conclusions

Desmoid tumors constitute one of the most important extraintestinal manifestations of FAP because they are associated with increased morbidity and mortality. Intra-abdominal desmoid disease represents 30% of cases. CT scan and MRI are used to delineate the anatomical location and extension of the tumor whereas diagnosis is confirmed by pathology and immunohistostaining. Management is challenging and should start with upper and lower endoscopy to exclude underlying polyposis syndromes. Medical therapy is preferred in uncomplicated desmoid disease especially in the setting of FAP. Surgical resection, however, is secluded for sporadic desmoids.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

The authors have declared that no competing interests exist.

References

  • 1.An atypical presentation of small bowel obstruction and perforation secondary to sporadic synchronous intra-abdominal desmoid tumours. Abdalla S, Wilkinson M, Wilsher M, Uzkalnis A. Int J Surg Case Rep. 2016;20:147–150. doi: 10.1016/j.ijscr.2016.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Desmoid tumours complicating familial adenomatous polyposis. Clark SK, Neale KF, Landgrebe JC, Phillips RK. http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2168.1999.01222.x/full. Br J Surg. 1999;86:1185–1189. doi: 10.1046/j.1365-2168.1999.01222.x. [DOI] [PubMed] [Google Scholar]
  • 3.Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Saito Y, Hinoi T, Ueno H, et al. Ann Surg Oncol. 2016;23:559–565. doi: 10.1245/s10434-016-5380-3. [DOI] [PubMed] [Google Scholar]
  • 4.Mesenteric fibromatosis (desmoid tumour) - a rare case report. Mukut D, Ghalige HS, Santhosh R, Sharma MB, Singh TS. J Clin Diagn Res. 2014;8:1–2. doi: 10.7860/JCDR/2014/8520.5098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Growing in silence! Haddad FG, El Bitar S, Deeb L. Am J Gastroenterol. 2017;153:1203–1204. doi: 10.1053/j.gastro.2017.06.050. [DOI] [PubMed] [Google Scholar]
  • 6.Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, et al. Br J Cancer. 2011;104:37–42. doi: 10.1038/sj.bjc.6605997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy. Parc Y, Piquard A, Dozois RR, Parc R, Tiret E. Ann Surg. 2004;239:378–382. doi: 10.1097/01.sla.0000114216.90947.f6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES